Minoxidil 5 vs 7 percent: choose 5% unless a dermatologist or prescriber has a specific reason for a compounded 7% formula. No head-to-head trial shows 7% grows more hair than 5%. Five percent has stronger trial and product-label support. Seven percent may appear in prescription combinations, but those formulas cannot show that two extra percentage points improve results.
Minoxidil 5 vs 7 percent at a glance
| Decision point | 5% topical minoxidil | 7% topical minoxidil |
|---|---|---|
| Direct comparison | No direct 5%-versus-7% trial | No direct 5%-versus-7% trial |
| Evidence base | Randomized trials support 5% for pattern hair loss | No trial isolates a 7% advantage over 5% |
| Current market status | Standardized OTC products are sold in the US and UK | Some prescription or compounded combinations exist; status varies |
| Expected timing | Labels say results may start after two months; some people need longer | No evidence shows that 7% works faster |
| Irritation | Itching, redness and scaling can occur | Not tested directly against 5%; stronger formulas may irritate more |
| Best fit | The evidence-based default for most eligible readers | A clinician-led choice based on the complete formula |
There is no 5%-versus-7% trial
Singh and colleagues reviewed concentrations above 5% in Clinical and Experimental Dermatology in 2022. They found scattered studies at 10% and 15%, but no randomized 5%-versus-7% comparison. Higher strengths sometimes did better, sometimes did not, and local irritation tended to rise.
The missing trial matters. You cannot compare a 5% study with a separate 7% product testimonial and call 7% superior. Different participants, vehicles, schedules, endpoints and added drugs can change the result.
Five percent has direct randomized evidence against lower strengths. Olsen and colleagues randomized 393 men with androgenetic alopecia to 5%, 2% or placebo for 48 weeks. The 5% group had 45% more hair regrowth than 2% at week 48. It also had more itching and local irritation.
The dose-response does not follow a proven straight line. Ghonemy, Alarawi and Bessar randomized 90 men to 5%, 10% or placebo for 36 weeks. Five percent produced larger vertex and frontal hair-count changes than 10%. The 10% group had more initial shedding, contact dermatitis and unwanted hair growth.
This does not prove 7% is worse. It shows why a higher percentage cannot be treated as a guaranteed upgrade.
What is actually sold as 5% or 7%?
Five percent is a mainstream, standardized topical strength. Sun Pharmaceutical's US DailyMed label, checked 6 November 2026, lists an approved OTC 5% minoxidil solution. It is for men with gradual vertex thinning. Labels still vary by sex, country and foam versus liquid.
In the UK, McNeil's Regaine label in emc was checked on 6 November 2026. It lists a 5% w/v minoxidil solution for men aged 18 to 65 as a general-sale medicine. Its instructions specify 1 mL twice daily and no more than 2 mL each day.
A UK 7% example makes the comparison problem clearer. The Hims UK help page, checked 6 November 2026, lists a four-active spray. It contains 7% minoxidil, 0.3% finasteride, 2.2% ketoconazole and 0.2% biotin. That is not a test of 7% minoxidil alone.
Seven percent is real, but its product context changes the claim. A Sincerus US DailyMed label, checked 6 November 2026, lists a prescription solution with 7% minoxidil and 4% niacinamide. Its marketing category is “unapproved drug other.” It is not an FDA-approved 7% minoxidil-only medicine.
A DailyMed listing is not proof of approval or greater effectiveness. A 7% offer may be compounded or combined with another active. If it works, the extra minoxidil may not be the reason. You cannot transfer a 5% label's directions or safety evidence to a different formula.
Will 7% work faster or rescue a poor response?
No direct trial answers either question. The US 5% label says results may appear after two months, while some men need at least four. The UK label says two months or more, and continued use is needed to maintain regrowth.
Moving to 7% after eight weeks confuses time with dose. A slow response might reflect normal timing, inconsistent application, the wrong diagnosis or an irritating formula. The full minoxidil results timeline explains what can reasonably be judged at each stage.
Early shedding can also mislead you. It may occur after starting minoxidil and does not prove failure. Severe or persistent shedding deserves medical review. Read the guide to the minoxidil shedding phase before changing strength for that reason.
Tolerance affects results because a formula used consistently has a chance to work. If liquid stings or flakes, changing the vehicle may make more sense than raising the concentration. The foam-versus-liquid comparison helps separate a strength question from a vehicle question.
A practical decision path
- Confirm the pattern. Topical labels target gradual pattern thinning. Sudden, patchy, postpartum or unexplained loss needs professional assessment first.
- Read the whole formula. A 7% combination is not a clean test against 5% minoxidil alone.
- Allow enough time. Follow the actual label or prescription, then compare consistent photos over months rather than days.
- Change course for a reason. Poor tolerance, no response or an uncertain diagnosis calls for reassessment, not an automatic jump in strength.
For a consistent starting view, the hairline photo check can keep visible outline measurements when its optional tracker is enabled. It cannot diagnose hair loss or prove that minoxidil caused a change.
When a doctor should decide
A clinician should make the call before any 7% compounded or combination prescription. Get assessed first if hair loss is sudden, patchy, painful, inflamed or unexplained. A family history does not rule out another cause.
Stop and seek medical advice for chest pain, a rapid heartbeat, faintness, dizziness, swollen hands or feet, or unexplained weight gain. The 5% label also advises asking a doctor first if you have heart disease.
Scalp redness or irritation deserves attention too. Higher concentrations can require different solvents, and the 2022 review linked stronger formulas with more local effects. The vehicle can also irritate, so percentage alone does not identify the cause.
Pregnancy, breastfeeding, age limits and approved use differ by product and country. Follow the exact label and prescriber, not a concentration comparison on its own.
How to decide
For most readers choosing between an OTC 5% product and an unfamiliar 7% offer, 5% is the evidence-based default. It has direct trial support, standardized labels and clearer safety instructions. Seven percent is a clinician-led option when the whole compounded formula has a specific rationale.
Professional review should come before switching if 5% has failed after a fair trial, causes persistent irritation or the diagnosis is uncertain. The evidence does not separate 5% from 7% on hair growth. Until a head-to-head trial does, paying for the larger number is a bet, not an evidence-backed upgrade.
Oscar Nascimento
Editorial writer, GlowUp Face
Oscar writes about evidence-based skin care, healthcare, looksmaxxing, and the social and economic research surrounding appearance.
Full profile and all articles →
